Crohn's Disease Clinical Trials in St Louis, Missouri
8 studies are recruiting for crohn's disease in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Specialists In Gastroenterology /ID# 283939, St Louis, Missouri
- Locations
- 36 in total
- Run by
- AbbVie
-
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…
- Stage
- Phase 3
- Ages
- 16 to 80
- Site
- Washington University School of Medicine ( Site 5058), St Louis, Missouri
- Locations
- 499 in total
- Run by
- Merck Sharp & Dohme LLC
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …
- Stage
- Phase 4
- Ages
- 18 to 70
- Site
- Washington University School of Medicine, St Louis, Missouri
- Locations
- 48 in total
- Run by
- Takeda
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…
- Stage
- Phase 3
- Ages
- 18 to 70
- Site
- Washington University School of Medicine, St Louis, Missouri
- Locations
- 183 in total
- Run by
- Eli Lilly and Company
-
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…
- Stage
- Phase 3
- Ages
- 2 to 19
- Site
- Washington University School of Medicine, St Louis, Missouri
- Locations
- 68 in total
- Run by
- Eli Lilly and Company
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Washington University /ID# 266938, St Louis, Missouri
- Locations
- 255 in total
- Run by
- AbbVie
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-…
- Stage
- Phase 3
- Ages
- 16 to 80
- Site
- Gateway Gastroenterology-Site Number: 8400097, St Louis, Missouri
- Locations
- 35 in total
- Run by
- Sanofi
-
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up…
- Stage
- Phase 2
- Ages
- 18 to 75
- Site
- Investigational Site Number: 8400013, St Louis, Missouri
- Locations
- 66 in total
- Run by
- Sanofi
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.